GeoVax Labs vs 60 Degrees Pharmaceuticals
GOVX and SXTP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GOVX and SXTP compare
60 Degrees Pharmaceuticals is the larger company, worth 2.5 times as much as GeoVax Labs ($1.8M against $718K).
60 Degrees Pharmaceuticals grew revenue faster over the last twelve months (73.2% versus −100% for GeoVax Labs).
60 Degrees Pharmaceuticals scores higher on the StockData Score (8 against 7 for GeoVax Labs), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GOVX | SXTP |
|---|---|---|
| Size and price | ||
| Market cap | $718K | $1.8M |
| Share price | $1.71 | $0.518 |
| Change, 1 year | −86.3% | −89.5% |
| Change, 5 years | −100.0% | – |
| Beta (5Y) | – | 2.09 |
| Employees | 19 | 3 |
| StockData Score | ||
| Total score | 7 | 8 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 1.6× |
| P/B | 0.6× (better) | 0.7× |
| FCF yield | −2299% | −488% (better) |
| Fair value | – | $1.29 |
| Margin of safety | – | 59.7% |
| Growth | ||
| Revenue growth (TTM) | −100% | 73.2% (better) |
| Revenue growth, 5Y average | 6.4% | – |
| Profitability | ||
| Gross margin | – | 19.4% |
| Operating margin | – | −775% |
| Net margin | – | −730% |
| FCF margin | – | −801% |
| Return on equity | −603% | −322% (better) |
| Return on invested capital | – | −659% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 (better) |
| Interest coverage | – | −1134.8× |
| Current ratio | 1.46 | 2.32 (better) |
| Altman Z-score | −84.45 | −22.23 (better) |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 117% | 21.5% |
| Held by insiders | 47.4% | 21.0% |
| Insider net buying, 12 months | $0 | $30.1K (better) |
| Short interest, % of float | 79.5% | – |
Go deeper
- GOVX stock overview
- GOVX income statement
- GOVX valuation and score
- SXTP stock overview
- SXTP income statement
- SXTP valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.